Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and 18F-FDG-PET/CT in correlation to clinical pathologic outcome.

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 07/08/2020.
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_2665FFBF2930
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and 18F-FDG-PET/CT in correlation to clinical pathologic outcome.
Périodique
Journal of nuclear medicine
Auteur(s)
Jreige M., Dunet V., Letovanec I., Prior J.O., Meuli R.A., Beigelman-Aubry C., Schaefer N.
ISSN
1535-5667 (Electronic)
ISSN-L
0161-5505
Statut éditorial
Publié
Date de publication
21/06/2019
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
Rationale: To investigate the performance of high-resolution computed tomography (HRCT) versus <sup>18</sup> F-FDG-PET/CT for the diagnosis of pulmonary lymphangitic carcinomatosis (PLC). Methods: In this retrospective institutional approved study, ninety-four patients addressed for initial staging of lung cancer with suspicion of PLC were included. Using double blind analysis, we assessed the presence of signs favoring PLC on HRCT (smooth or nodular septal lines, subpleural nodularity, peribronchovascular thickening, satellite nodules, lymph node enlargement and pleural effusion). <sup>18</sup> F-FDG-PET/CT images were reviewed to qualitatively evaluate peritumoral uptake and to quantify tracer uptake in the tumoral and peritumoral areas. Histology performed on surgical specimens served as gold standard in all patients. Results: Among 94 included patients, 73% (69/94) had histologically confirmed PLC. Peribronchovascular thickening, lymph nodes involvement and increased peritumoral uptake were more often present in patients with PLC (p<0.009). Metabolic variables including tumor SUV <sub>max</sub> , SUVmean, "metabolic tumor volume" (MTV) and total lesion glycolysis (TLG) as well as peritumoral SUV <sub>max</sub> , SUVmean and their respective ratios to background were significantly higher in PLC group versus the non-PLC group (p≤0.0039). Sensitivity, specificity, and ROC area [95%CI] of peribronchovascular thickening (69%, 83% and 0.76 [0.67-0.85]) and increased peritumoral uptake (94%, 84% and 0.89 [0.81-0.97]) were similar (P = 0.054). Peritumoral SUV <sub>max</sub> and SUVmean had a significantly higher sensitivity, specificity, and ROC area of 97%, 92% and 0.98 [0.96-1.00] and 94%, 88% and 0.96 [0.92-1.00] for detecting PLC (all p≤0.025). Conclusion: Qualitative evaluation of <sup>18</sup> F-FDG-PET/CT and HRCT have similar performance for the diagnosis of PLC, both being outperformed by <sup>18</sup> F-FDG-PET/CT quantitative parameters.
Mots-clé
FDG, HRCT, Molecular Imaging, Oncology: Lung, PET/CT, Pulmonary lymphangitic carcinomatosis, lung cancer
Pubmed
Création de la notice
15/07/2019 16:22
Dernière modification de la notice
21/08/2019 6:08
Données d'usage